Clinical Result Of Novel Extended Depth Of Focus Intraocular Lens
Published 2023 - 41st Congress of the ESCRS
Reference: PO0507 | Type: Free paper | DOI: 10.82333/e5vk-mw57
Authors: Bartłomiej Markuszewski* 1 , Adam Wylęgała 2 , Anna Markuszewska 3 , Ewa Wróblewska-Czajka 4 , Magdalena Nandzik 4 , Edward Wylęgała 4
1Wroclaw Eye Center,Wroclaw,Poland; Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences,Medical University of Silesia,Katowice,Poland, 2Department of Ophthalmology,District Railway Hospital in Katowice,Katowice,Poland;Department of Pathophysiology,Medical University of Silesia,Katowice,Poland, 3Wroclaw Eye Center,Wroclaw,Poland, 4Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences,Medical University of Silesia,Katowice,Poland
Purpose
The purpose of this study is to present the first early postoperative clinical and patient reported outcomes with implantation of an extended depth of focus (EDOF) Baush & Lomb LuxSmart intraocular lenses (IOL) in a private hospital setting in patient with cataracts and presbyopia targeted for emmetropia.
Setting
Private hospital setting - Wroclaw Eye Center, Wroclaw, Poland.
Methods
The analysed group consisted of outcomes of 65 eyes of 37 consecutive patients who recently underwent a cataract removal surgery with implantation of LuxSmart (Baush & Lomb, Vaughan, Ontario, Canada) IOL. The mean age was 64.5 ± 10.6 years; 55.2% were male and 44.8% were female patients. Inclusion criteria were primary procedure with no previous refractive surgery, emmetropic aim in each eye, preop corneal astigmatism 1.50 D or less and absence of any ocular pathology. Postop UDVA, UNVA, patient reported outcomes and adverse events were assessed at 1 and 3 months. IOL was calculated by Barrett Universal II formulae with the use of ACE biometry.
Results
Implanted IOL power ranged from +10.0 to +30.0 dsph with average +21.0 dsph +/- 3.5. Best distance and near-uncorrected vision were significantly better. Postop UCDVA yielded logMAR 0.1 +/- 0.1, UCNVA J2 was reached in 37 eyes (56,9%) from 50cm, J4 in 54 eyes (83.1%). Mean refractive target -0.2 +/- 0.3 D and after surgery 0.07 +/- 0.50 D (p<0.01). No IOL dislocation was observed. In cohort surgery two incidence of blocked IOL in cartridge were observed, requiring usage of another lens packed injector cartridge. No adverse effects were noticed. VF-14 test questionnaire yielded 84.2 +/- 3.4 points. IOP post-surgery showed no significant differences. Visual effect were minimally reported.
Conclusions
Implantation of this novel Baush & Lomb LuxSmart IOL seems to be good option in presbyopic patients with cataract. This extended depth of focus lens gives patient high satisfaction with maximum visual acuity for distance and near reached in majority of patients.